THE EXPERIENCE AND RESULTS OF CYTOREDUCTIVE SURGERY AND HIPEC USED IN ADVANCED OVARIAN CANCER

Abstract

The research object was life quality of patients with ovarian cancer after complex treatment. Nowadays cytoreductive surgery and HIPEC is the mainstay of management of advanced stages ovarian cancer. Description of the problem: study was conducted to assess the effectiveness of combined treatment in IIIA-IIIC ovarian cancer, its impact on quality of life. Main scientific results: 37 patients of main group (CRS + HIPEC) were compared with 25 patients of control group (surgery + systemic chemotherapy). The quality of life was assessed with Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Comparative analysis of quality of life 6 months after treatment completion did not show significant statistical difference. Combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer, is tolerated better and has less systemic toxicities than systemic chemotherapy. The area of practical use of research results: hyperthermic intraperitoneal chemotherapy is performed for patients suffering from malignant tumors of the abdominal cavity, including metastatic colon cancer, ovarian cancer, stomach cancer, pseudomyxoma, mesothelioma, rhabdomyosarcoma, and some other types of oncology. Innovative technological product: combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer. Scope of application of an innovative technological product: HIPEC is an innovative treatment option for advanced cancer that has spread to the abdominal cavity (carcinomatosis) and has not gone beyond it.